JPWO2020010108A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020010108A5
JPWO2020010108A5 JP2021500148A JP2021500148A JPWO2020010108A5 JP WO2020010108 A5 JPWO2020010108 A5 JP WO2020010108A5 JP 2021500148 A JP2021500148 A JP 2021500148A JP 2021500148 A JP2021500148 A JP 2021500148A JP WO2020010108 A5 JPWO2020010108 A5 JP WO2020010108A5
Authority
JP
Japan
Prior art keywords
agent
cells
tslp
pharmaceutical according
innate immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500148A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595564B2 (ja
JP2021529208A5 (https=
JP2021529208A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040343 external-priority patent/WO2020010108A1/en
Publication of JP2021529208A publication Critical patent/JP2021529208A/ja
Publication of JPWO2020010108A5 publication Critical patent/JPWO2020010108A5/ja
Publication of JP2021529208A5 publication Critical patent/JP2021529208A5/ja
Application granted granted Critical
Publication of JP7595564B2 publication Critical patent/JP7595564B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500148A 2018-07-05 2019-07-02 がんを処置するための医薬剤を局所送達するための組成物および方法 Active JP7595564B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694100P 2018-07-05 2018-07-05
US62/694,100 2018-07-05
US201862740514P 2018-10-03 2018-10-03
US62/740,514 2018-10-03
PCT/US2019/040343 WO2020010108A1 (en) 2018-07-05 2019-07-02 Compositions and methods for local delivery of pharmaceutical agents to treat cancer

Publications (4)

Publication Number Publication Date
JP2021529208A JP2021529208A (ja) 2021-10-28
JPWO2020010108A5 true JPWO2020010108A5 (https=) 2022-07-11
JP2021529208A5 JP2021529208A5 (https=) 2022-07-11
JP7595564B2 JP7595564B2 (ja) 2024-12-06

Family

ID=69059932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500148A Active JP7595564B2 (ja) 2018-07-05 2019-07-02 がんを処置するための医薬剤を局所送達するための組成物および方法

Country Status (5)

Country Link
US (2) US20210177831A1 (https=)
EP (1) EP3817774A4 (https=)
JP (1) JP7595564B2 (https=)
CN (1) CN112654368B (https=)
WO (1) WO2020010108A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
WO2021206158A1 (ja) * 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2022020655A1 (en) * 2020-07-23 2022-01-27 The Regents Of The University Of Colorado, A Body Corporate Method for treating melanoma
CN116024175A (zh) * 2021-10-27 2023-04-28 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280690C1 (en) * 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
WO2012061630A2 (en) * 2010-11-04 2012-05-10 442 Ventures, Llc Composition and method for treating skin conditions
WO2015070031A1 (en) * 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Similar Documents

Publication Publication Date Title
Calvet et al. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells
Weichselbaum et al. Radiotherapy and immunotherapy: a beneficial liaison?
Heller et al. Gene electrotransfer clinical trials
JP2021529208A5 (https=)
Huang et al. The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy
Tai et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells
Peng et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
Wachowska et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy
JP2023507861A (ja) がん細胞への交流電場の印加及びチェックポイント阻害剤の投与によってがん細胞の生存率を低下させる方法
Campana et al. Treatment of metastatic melanoma with electrochemotherapy
US20230398369A1 (en) Method and apparatus for cancer treatment
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
Rekers et al. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives
Holldack Toll-like receptors as therapeutic targets for cancer
Bhaliya et al. New horizons in cancer immunotherapy: The evolving role of R848 and R837
JP7376678B2 (ja) Ｍ１マクロファージを有効成分として含む癌細胞標的型薬物送達体及び光熱治療効果増進用組成物
JPWO2020010108A5 (https=)
US20080187556A1 (en) Medicine for Treating Tumor and Use Therefor in Preparation of the Medicaments for Treating Tumor
Kim et al. Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T cells in peritoneal space
CN116585315A (zh) 用于调节pd-1信号转导的组合物
US11242372B2 (en) IFN beta protein analogs
CN114917335A (zh) 抗PD-1抗体与IFN-α联合在制备抗肿瘤药物中的用途
CN106075454A (zh) 一种抗肿瘤药物制剂组合
JP6663438B2 (ja) 癌および皮膚病変の治療